Myriad Genetics Q1 Revenues Fall 3 Percent | GenomeWeb

This article has been updated to include information from Myriad's 10-Q filing and stock pricing information.

NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its first quarter revenues in fiscal 2017 fell 3 percent, thanks in part to an 11 percent drop in hereditary cancer testing revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.